In order to develop a treatment for Epidermolysis Bullosa – commonly known as EB treatments, Abeona Therapeutics Inc. (NASDAQ:ABEO), EB Medical Research Foundation and EB Research Partnership have joint development resources so as to have a more productive study force into the development of gene therapy treatments.

What is Epidermolysis Bullosa

EB, or rather Epidermolysis Bullosa is a highly consequential and rare genetic skin disorder which mainly impact children resulting in painful skin blisters as well as erosions all over the body. One of the harshest forms of Epidermolysis Bullosa is Recessive Dystrophic Epidermolysis Bullosa (RDEB).

RDEB is characterized by severe chronic skin blistering, joint contractures, wounds that remain open and consistently painful, esophageal strictures, pseudo syndactyly, corneal abrasions as well as a shortened life span.

The merger between these corporation’s aids in both bolstering research strength and diminishing any detrimental weaknesses that a corporation may suffer by itself. Which aids in a more effective development of gene therapies for this devastating disease.

Steven H. Rouhandeh, the Executive of Abeona Therapeutics announced that they were proud to be working with EB Medical Research Foundation as well as EB Research Partnership as well as Stanford University in order to accelerate promising products into being ready for commercialization purposes.

Alexander Silver, co-founder, and Chairman, EBRP stated that this joint effort from these three organizations emphasizes dedication on the mission to commercialize a treatment to aiding and eventually curing epidermolysis bullosa.

The clinical trial results (Phase One) for the lead EP program, EB-101 which is mainly responsible for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) was presented at the opening Plenary Session of the Society for investigative Dermatology in May 2016.

Investigators based at Stanford university are now working on recruiting patients in order to proceed with phase 2 of the treatment development.

The gene therapy treatments that are being implemented in order to cure EB, were developed at the Stanford University School Of Medicine and furthermore, these products are exclusively licensed to Abeona.